Lorundrostat
Mineralys Therapeutics (MLYS)
Decision dateDec 22, 2026
37 days away
Marketer take
Would compete directly with the recently approved Baxfendy in add-on hypertension, so expect head-to-head positioning in primary care.
- Sponsor company
- Mineralys Therapeutics (MLYS)
- Indication
- Hypertension, in combination with other antihypertensives
- Therapeutic area
- Cardiovascular
- Event
- PDUFA target action date
- Date
- Dec 22, 2026
- Status
- Upcoming
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?